ACG New York Women of Leadership - Entrepreneur Series
Barbara Bradley Baekgaard, founder of Vera Bradley (Nasdaq: VRA), is the latest in a series of entrepreneurs highlighted at ACG New York Women of Leadership events. Photo credit: Robert Blumenfeld


GTCR, Hormel, the Riverside Co-CEOs and Others Win M&A Mid-Market Awards
Amid a slow and challenging year for dealmaking, the winners of Mergers & Acquisitions’ 7th Annual M&A Mid-Market Awards outpaced the competition to grow, innovate and lead the middle market


Financial Services Companies Heat Up M&A Market
Speakers from Flexpoint Ford, Genstar Capital, Baird Capital, Madison Capital Funding and Katten Muchin Rosenman discuss the various factors playing a role in M&A activity within the financial services space

Expert's Corner

Pursuing Pharma Manufacturing
The fragmented pharmaceutical manufacturing industry provides plenty of opportunities for private equity investors, says JLL Partners founder Paul Levy

Today's Transactions:
Pernix Therapeutics Buys Cypress and Hawthorn Pharmaceuticals for $101M

Cypress produces generic medication and Hawthorn makes branded medication

Pernix Therapeutics Holdings Inc. (NYSE: PTX) will purchase Cypress Pharmaceutical Inc., a privately-held company that makes generic pharmaceuticals, and Hawthorn Pharmaceuticals Inc., a company that makes branded pharmaceuticals for up to $101 million.

The buyer, a specialty pharmaceutical company based in the Woodlands, Texas, will make an upfront payment of $68.5 million in cash and $12.5 million in equity. The company has a $60 million credit facility arranged by MidCap Financial.

Both targets are headquartered in Madison, Miss., and combined have about $50 million in revenue.

Pernix expects the deal to increase its branded and generic portfolio. The deal is subject to regulatory approval.


For more information on related topics, visit the following: